ÂÜÀòÂÒÂ×

Dr. Richard Soll is presently Senior Advisor, Strategic Initiatives at WuXi AppTec and Head of the WuXi office in Boston, Massachusetts. At WuXi AppTec he served as Senior Vice President including head of the medicinal chemistry in the International Discovery Service Unit, business development, and corporate alliances.

Dr. Soll’s contributions led to the discovery of the HCV NS5A inhibitor in the Merck-WuXi partnership, the JAK2 inhibitor fedratinib at TargeGen (partnered with Celgene/BMS), and more than 10 other clinical stage drugs throughout his career.

Dr. Soll is a board observer for Magnolia and Proniras and is an advisory board member with the Blavatnik Center for Drug Discovery at Tel Aviv University, the Children’s Tumor Foundation, and the Pistoia Alliance.

Dr. Soll was CSO/VP at TargeGen and VP Chemistry at 3-Dimensional Pharmaceuticals. He received his Ph.D. in chemistry at Dartmouth College and was a post-doctoral fellow at Harvard.